Abbott Laboratories (ABT) Q1 2026 (USD): Adj. EPS 1.15 (exp. 1.15), Revenue 11.2bln (exp. 11.00bln)
Outlook
- Q2 adj. EPS 1.25-1.32 (exp. 1.37).
- FY26 adj. EPS 5.38-5.58 (exp. 5.61).
Context
Abbott Laboratories reported Q1 adjusted EPS that met expectations while revenue slightly beat projections, suggesting stable demand in the health care sector. However, the guidance for Q2 and FY26 is below consensus, indicating potential challenges ahead that could weigh on sentiment and future performance. This mixed outcome may lead traders to reassess the stock's valuation and expectations in the context of broader market dynamics.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#ABBOTT LABORATORIES#ABT.US#FOREX#EQUITIES#METALS#EU SESSION#US SESSION#HEALTH CARE EQUIPMENT#METALS & MINING#HEALTH CARE EQUIPMENT & SUPPLIES#HEALTH CARE EQUIPMENT & SERVICES (GROUP)#S&P 500 INDEX#ABT#DXY#US EQUITIES